![Evil or Very Mad :evil:](./images/smilies/icon_evil.gif)
![Evil or Very Mad :evil:](./images/smilies/icon_evil.gif)
![Rolling Eyes :roll:](./images/smilies/icon_rolleyes.gif)
Here is a recent study on Niaspan - study was stopped when a small increase in ischemic stroke was noted among those taking Niaspan compared to those taking placebo and implications on Abbott and Biosciences.
http://www.pharmatimes.com/article/11-0 ... ulled.aspx
Abbott's Niaspan fails to prevent heart attacks, trial pulled
WORLD NEWS | MAY 27, 2011
http://www.forbes.com/feeds/ap/2011/05/ ... 88536.html
Excerpt : A week earlier a panel of health advisers said another Abbott drug, Trilipix, should be re-labeled to indicate that it failed to lower heart attacks in a study of diabetics. Trilipix is a fibrate, a drug that lowers blood fats called triglycerides while boosting "good cholesterol."